SCHEMBL4209665

SCHEMBL4209665

Cc1ncc(-c2nc(NC3CCN(S(=O)(=O)CCC(C)(C)N)CC3)ncc2Cl)n1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 10/20 0.44
CCNE1 P24864 8/20 0.44
CDK1 P06493 4/20 0.44
CCNB1 P14635 3/20 0.44
CCNB2 O95067 2/20 0.44
CCNE2 O96020 2/20 0.44
CDK5 Q00535 2/20 0.44
CDK5R1 Q15078 2/20 0.44
CCNB3 Q8WWL7 2/20 0.44
CCND1 P24385 12/20 0.41
CDK6 Q00534 12/20 0.41
CDK4 P11802 10/20 0.41
CCND3 P30281 9/20 0.41
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
JUN P05412 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504912 0.90 CDK2 (0.43) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4200836 0.90 CDK2 (0.48) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4494710 0.89 CDK2 (0.42) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4491979 0.85 CDK2 (0.45) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4495234 0.84 CCNE1 (0.61) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4514561 0.84 CDK2 (0.46) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4207075 0.81 CDK2 (0.47) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4196282 0.80 CDK2 (0.51) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4202739 0.79 CDK2 (0.46) CDK2CCNE1CDK1CCNB1CCNB2
SCHEMBL4202745 0.77 MAPK8 (0.51) CDK2CCNE1CDK1CCNB1CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-11-05 US disclosed
EP-2032559-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2009-03-11 EP disclosed
WO-2007138268-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION CCNI, MKI67, CDK2 CDK2 3/4885CCNE1 17/4885CDK1 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.